Status:
RECRUITING
MRE for Assessment of Histopathological Growth Patterns in Colorectal Liver Metastases
Lead Sponsor:
Shengjing Hospital
Conditions:
Metastatic Colorectal Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
The goal of this study is to investigate the value of MR elastography-based SII as a means of detecting HGP noninvasively in patients with pathology-proven CRLM. MRE will provide a direct measure of t...
Detailed Description
Colorectal cancer ranks third in terms of incidence and second in terms of mortality among all cancers on the global cancer burden, based on the GLOBOCAN 2020 estimates. Among people diagnosed with co...
Eligibility Criteria
Inclusion
- Diagnosed CRLM
- Pathologic results obtained in surgical patients
- No contraindications for magnetic resonance imaging examination
Exclusion
- Image quality does not meet the measurement requirements.
- the diameter of CRLM \<1cm
- Combined with other important organ dysfunction
- Combined with malignant tumor
- Patients who do not sign an informed consent
- Patients with metallic implants or foreign bodies in their bodies (pacemakers, artificial metallic heart valves, metal joints, metal implants, and those who cannot remove dentures, insulin pumps, or contraceptive rings)
Key Trial Info
Start Date :
December 24 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 24 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06208397
Start Date
December 24 2023
End Date
December 24 2026
Last Update
May 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China, 110004